WS Investor
05 Dec 2025, 14:59
Edwards Lifesciences Reaffirms Growth Strategy and Provides 2026 Outlook
Edwards Lifesciences reiterated its long-term strategy for sustainable, differentiated growth during its annual investor conference, highlighting its leadership across transcatheter aortic, mitral and tricuspid therapies. CEO Bernard Zovighian said the company is entering 2026 with strong momentum as it advances first-of-its-kind innovations for structural heart conditions, including emerging opportunities in aortic regurgitation and structural heart failure.
The company reaffirmed its 2025 guidance and forecasted 2026 constant-currency sales growth of 8 to 10 percent, with adjusted EPS of 2.80 to 2.95 dollars. Growth is expected across all major segments, including TAVR sales of 4.6 to 4.9 billion dollars at 6 to 8 percent growth, and TMTT sales of 740 to 780 million dollars at up to 45 percent growth. Edwards also anticipates approximately 100 basis points of operating-margin expansion despite planned dilution from the JenaValve acquisition.
Upcoming regulatory and clinical milestones include U.S. guideline updates for TAVR by late 2026, FDA approval of the SAPIEN M3 mitral valve in early 2026, and pivotal trial results expected throughout the year. Edwards highlighted its expanding pipeline, continued global adoption of its SAPIEN platform, and long-term target of roughly 10 percent average annual sales growth driven by both established and emerging structural heart therapies.
Edwards Lifesciences reiterated its long-term strategy for sustainable, differentiated growth during its annual investor conference, highlighting its leadership across transcatheter aortic, mitral and tricuspid therapies. CEO Bernard Zovighian said the company is entering 2026 with strong momentum as it advances first-of-its-kind innovations for structural heart conditions, including emerging opportunities in aortic regurgitation and structural heart failure.
The company reaffirmed its 2025 guidance and forecasted 2026 constant-currency sales growth of 8 to 10 percent, with adjusted EPS of 2.80 to 2.95 dollars. Growth is expected across all major segments, including TAVR sales of 4.6 to 4.9 billion dollars at 6 to 8 percent growth, and TMTT sales of 740 to 780 million dollars at up to 45 percent growth. Edwards also anticipates approximately 100 basis points of operating-margin expansion despite planned dilution from the JenaValve acquisition.
Upcoming regulatory and clinical milestones include U.S. guideline updates for TAVR by late 2026, FDA approval of the SAPIEN M3 mitral valve in early 2026, and pivotal trial results expected throughout the year. Edwards highlighted its expanding pipeline, continued global adoption of its SAPIEN platform, and long-term target of roughly 10 percent average annual sales growth driven by both established and emerging structural heart therapies.
